UBI gets first test-strip order from Siemens
Universal Biosensors (ASX:UBI) has received its first commercial order from Siemens Healthcare Diagnostics for the supply of test strips for a point-of-care coagulation testing product.
The order for the production and supply of PT-INR test strips is a key milestone in the two companies’ collaboration to develop handheld coagulation testing devices.
The Siemens PT-INR testing system is designed to monitor the application of anti-coagulant therapy Warfarin. Pending regulatory approvals, the system is on track to launch by the end of the third quarter.
Universal Biosensors will manufacture the PT-INR strips for the order at its Rowville, Victoria, plant.
The company’s collaboration with Siemens involves the development of three point-of-care testing products designed to provide laboratory-quality results.
“The receipt of this first commercial order is a major step forward in our program with Siemens towards our shared vision for bringing a range of new products to the point-of-care coagulation testing market,” Universal Biosensors CEO Paul Wright commented.
Universal Biosensors (ASX:UBI) shares were trading 23.08% higher at $0.24 as of around 1.30 pm on Tuesday.
Could this psychedelic compound reduce post-concussion symptoms?
Few effective therapies exist for concussion. Now, an Australian clinical trial is exploring...
Turning point — optimal antibiotics for golden staph bloodstream infections
Involving more than 150 hospitals across more than 14 countries, a global clinical trial supports...
Alloy implants that naturally dissolve after healing
Australian researchers have been developing biodegradable magnesium-based alloys that more...
